Pancreatic Cancer Research

ResearcherCapital Medical UniversityActive in the last 2 years

Cheng Ding

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5911-5588; OpenAlex author ID A5101797148, A5108326240. Sources: OpenAlex.

Their work

Papers
11 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
1
Collaborators
25
Papers, trials and grants by year

2020: 3 papers · 2021: 4 papers · 2022: 1 paper · 2023: 2 papers · 2024: none · 2025: 1 paper

Papers 11

  1. Looking at or beyond the tumor - a systematic review and meta-analysis of quantitative imaging biomarkers predicting pancreatic cancer prognosis. Last author DOI 10.1007/s00261-025-04919-7↗
  2. Prognostic Value for Perioperative Serum Total Cholesterol Level on Postoperative Long-Term Prognosis of Pancreatic Cancer: A Retrospective Clinical Study. First author DOI 10.3390/diagnostics13081402↗
  3. Collagen type VII α1 chain: A promising prognostic and immune infiltration biomarker of pancreatic cancer. Co-author DOI 10.3892/ol.2023.13663↗
  4. Construction and Validation of a Necroptosis-Related Gene Signature for Predicting Prognosis and Tumor Microenvironment of Pancreatic Cancer. Co-author DOI 10.1155/2022/9737587↗
  5. Comparison of minimal invasive versus open radical antegrade modular pancreatosplenectomy (RAMPS) for pancreatic ductal adenocarcinoma: a single center retrosp… Co-author DOI 10.1007/s00464-020-07938-1↗
  6. Radical antegrade modular pancreatosplenectomy (RAMPS) versus conventional distal pancreatosplenectomy (CDPS) for left-sided pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00595-020-02203-3↗
  7. ROBO2 hampers malignant biological behavior and predicts a better prognosis in pancreatic adenocarcinoma. Co-author DOI 10.1080/00365521.2021.1930144↗
  8. CD44+ Circulating Tumor Endothelial Cells Indicate Poor Prognosis in Pancreatic Ductal Adenocarcinoma After Radical Surgery: A Pilot Study. Co-author DOI 10.2147/cmar.s309115↗
  9. Research Progress on Slit/Robo Pathway in Pancreatic Cancer: Emerging and Promising. Co-author DOI 10.1155/2020/2845906↗
  10. Glutathione S-Transferase Mu-3 Predicts a Better Prognosis and Inhibits Malignant Behavior and Glycolysis in Pancreatic Cancer. Co-author DOI 10.3389/fonc.2020.01539↗
  11. Tumor microenvironment in chemoresistance, metastasis and immunotherapy of pancreatic cancer. Co-author PMID 32774994↗

Closest collaborators

The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Menghua Dai · 8 shared papers, 2020–2023 · strength 1.16
  2. Shunda Wang · 5 shared papers, 2020–2021 · strength 0.66
  3. Xianlin Han · 3 shared papers, 2021–2025 · strength 0.54
  4. Hanyu Zhang · 3 shared papers, 2020–2021 · strength 0.39
  5. Yupei Zhao · 3 shared papers, 2020–2021 · strength 0.36
  6. Liang Zhu · 1 shared paper, 2025 · strength 0.30
  7. Zihe Wang · 1 shared paper, 2025 · strength 0.30
  8. Qiang Xu · 2 shared papers, 2021 · strength 0.24
  9. Taiping Zhang · 2 shared papers, 2021 · strength 0.24
  10. Junchao Guo · 2 shared papers, 2021 · strength 0.24
  11. Lei You · 2 shared papers, 2020 · strength 0.24
  12. Shaocheng Lyu · 1 shared paper, 2023 · strength 0.22
  13. Qiang He · 1 shared paper, 2023 · strength 0.22
  14. Jincan Huang · 1 shared paper, 2023 · strength 0.22
  15. Han-Xuan Wang · 1 shared paper, 2023 · strength 0.22
  16. Ren Lang · 1 shared paper, 2023 · strength 0.22
  17. Qiang He · 1 shared paper, 2022 · strength 0.19
  18. Cheng Xing · 1 shared paper, 2021 · strength 0.15
  19. Pengyu Li · 1 shared paper, 2021 · strength 0.15
  20. Yizhi Wang · 1 shared paper, 2021 · strength 0.14
  21. Jinshou Yang · 1 shared paper, 2020 · strength 0.13
  22. Quan Liao · 1 shared paper, 2021 · strength 0.12
  23. Qiaofei Liu · 1 shared paper, 2021 · strength 0.12
  24. Quan Liao · 1 shared paper, 2021 · strength 0.12
  25. Wenming Wu · 1 shared paper, 2021 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.